about
Melanized fungi in human diseaseIn vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.The use of pseudo-equilibrium constant affords improved QSAR models of human plasma protein bindingAnalysis of cerebrospinal fluid protein concentrations of patients with cryptococcal meningitis treated with antifungal agents.Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients.Hedgehog regulates cerebellar progenitor cell and medulloblastoma apoptosis.Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy.Tissue penetration of antifungal agents.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Impact of special patient populations on the pharmacokinetics of echinocandins.Formulation and delivery of itraconazole to the brain using a nanolipid carrier system.Intracranial Aspergillus granuloma.High weekly doses of liposomal amphotericin B as secondary prophylaxis after cerebral aspergillosis in a paediatric patient.HIV Immune Recovery Inflammatory Syndrome and Central Nervous System Paracoccidioidomycosis.Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis.Curcumin enhances the activity of fluconazole against Cryptococcus gattii-induced cryptococcosis infection in mice.Relationship between intracranial pressure and antifungal agents levels in the CSF of patients with cryptococcal meningitis.Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.Early fungal infection in an aortic prosthesis with probable cerebral metastasis: the success of a conservative strategy.Pharmacokinetics and distribution of voriconazole in body fluids of dogs after repeated oral dosing.Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM).Intracranial Aspergillosis in an Immunocompetent Young Woman.Effect of Efflux Transporter Inhibition on the Distribution of Fluconazole in the Rat Brain.[Diagnostic imaging methods and therapy options for cerebral aspergillosis].Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis.Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal MeningitisA Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in ChildrenResponding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside
P2860
Q24633163-9021545C-893D-4627-ABA3-CE4438D10800Q34058209-AF909DF2-83D9-4759-86BF-CD0CA5621A57Q34142328-CD9EFA72-80F8-4300-8C5B-EEF3E706F484Q34505582-29D215E5-6E78-4A56-83AC-51477446A34CQ35186490-55A6BC99-5DA7-4798-9153-80FF51315AC5Q35744569-4002BF56-AD87-461D-BD33-8AA7BA8E8E2EQ36161724-2C897D10-48A1-41E0-B67B-D8DC3D8FBBC5Q36359573-9B9D405F-CD46-4838-B814-70ED28CAE7A0Q37096795-531738A5-FA0F-413A-9F1F-E8A68083DA40Q37263320-5468CF9D-9374-45B1-9DA7-FBC5C9E26C0FQ37544911-5C295B37-0D90-44E4-90CC-39C72E5EC075Q37785979-61ECD73A-9D87-4E5D-9B1C-0C0DEF0613A2Q38420688-1735F169-1587-4473-8030-A15A33E5A2B6Q38462784-ACB677F6-127B-46DA-A25E-BFD771C67D5FQ39383964-648E001E-EEBB-43B3-BF52-E7EFA7444BE2Q39748689-47F133DF-7BE3-43AD-B777-8184B4D4279BQ39755518-18EE7A6C-D43C-4F34-8E2C-9336DA7FAA86Q40513188-7F198C15-CFEA-43C2-8D03-2A76607C3AD6Q40961271-686455FF-ABA2-4531-8DC8-839C70F725BBQ40963460-E8FECD9C-29A1-4A78-AD76-CC886CB89688Q41989505-13C94725-4202-4862-9491-C983BEFFEAFDQ42277828-A558EF83-5B0D-44B7-9537-070444C3A9E0Q43438440-A45B3698-62CE-4FD0-980A-7B18060E45D0Q44856263-1B8D47EF-0F22-406B-B8E0-ADEEAE6FBFEBQ47151374-783921E9-6899-4EA9-83AB-D4525AFD7892Q47239192-07DD2072-D803-49AE-82A6-8A2DBE2EC682Q47899652-7C46C463-CF2F-4E65-9A3B-7017D1612E26Q48247736-EFF959B0-0C2C-4F60-990E-3C2B616AAE88Q52888501-32154A63-499C-410F-8244-F41AB23AA067Q55488494-3A7B491D-BEA6-4AF9-B782-2F79088F9F27Q56910086-0E690D1F-A969-4C48-91F8-D4F54C44716CQ57730442-70FE8BEF-3D72-4E90-B68D-E7AC90C6C3DFQ58772251-C5803408-4E3D-473A-BCAB-1CEBF7E76623
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
CNS pharmacokinetics of antifungal agents.
@en
type
label
CNS pharmacokinetics of antifungal agents.
@en
prefLabel
CNS pharmacokinetics of antifungal agents.
@en
P2860
P356
P1476
CNS pharmacokinetics of antifungal agents.
@en
P2093
David Andes
Shravan Kethireddy
P2860
P304
P356
10.1517/17425255.3.4.573
P407
P577
2007-08-01T00:00:00Z